The investment team at Morgans has recently assessed several prominent ASX-listed companies, providing insights into their financial performances and future prospects. Among the firms reviewed are HMC Capital Ltd, Ramsay Health Care Ltd, and Sigma Healthcare Ltd. The broker’s evaluations indicate varying recommendations for investors, highlighting both opportunities and caution.
HMC Capital: Buy Recommendation
Morgans has retained a buy rating for HMC Capital Ltd (ASX: HMC), despite the company’s headline earnings falling short of expectations. The broker notes that HMC’s current valuation presents a potential buying opportunity. The price target has been adjusted to $4.45, down from $4.85.
The firm’s management fee revenue experienced a robust increase of 34% to $84.5 million, with assets under management (AUM) rising by 4% to $19.5 billion. Although the headline earnings per share (EPS) of 10.1 cents pre-tax were below consensus estimates, Morgans highlights the long-term value inherent in HMC. The broker points to a significant energy transition partnership expected to close by mid-2026, which is projected to strengthen the balance sheet and unlock a 5.7 gigawatt development pipeline.
Ramsay Health Care: Hold Amid Cost Challenges
In contrast, Ramsay Health Care Ltd (ASX: RHC) has received a hold rating from Morgans, despite reporting a first-half profit that exceeded expectations. The company benefited from lower finance charges and positive movements in non-controlling interests. Morgans has raised its price target for Ramsay to $40.77.
The operational performance was solid, driven by improved activity in Australia and stable conditions in Europe. Nevertheless, ongoing cost pressures and the early stages of a multi-year transformation program in Australia present challenges to the sustainability of profits. Morgans has adjusted its earnings forecasts for FY26 to FY28, reflecting these considerations.
Sigma Healthcare: Downgraded to Accumulate
Lastly, Sigma Healthcare Ltd (ASX: SIG) has seen its shares downgraded to an accumulate rating from a previous buy recommendation. The company’s latest half-year results were solid, aligning with market expectations. Morgans set a new price target of $3.36, slightly down from $3.39.
The highlights from Sigma’s performance include a 15% increase in like-for-like sales at Chemist Warehouse and revenue growth outpacing cost growth by 4.5%. While the company continues to track well against synergy targets, Morgans’ adjustments reflect modest downgrades to forecasts related to depreciation and amortization, as well as interest charges.
In summary, Morgans’ reviews of these ASX companies indicate a spectrum of investment opportunities, from HMC Capital’s potential growth to Ramsay Health Care’s cautious hold and Sigma Healthcare’s adjustment in rating. Investors should consider these insights carefully as they navigate the current market landscape.
